Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

With Its Economy Struggling, Spain Launches Second Cost-Cutting Exercise In Two Years

Executive Summary

Spain has become the latest European country to launch a comprehensive pharmaceutical sector reform, seeking to slice off €2.4 billion ($3.4 billion) from its annual drugs budget as part of a desperate attempt to boost its flagging economy.

You may also be interested in...



EU Transparency Directive Revisions May Accelerate Access To New Medicines, But IP Issues Set To Cause A Storm

Proposed revisions to the EU Transparency Directive could drive faster access to medicines. But innovative product sponsors say IP rules will damage their business.

Biopharma In 2011: A Year Of Transition

If 2010 was the year when pharma introduced new models, 2011 was the year it discovered that executing on its plans required a new mindset. There was a realization that pharma input and capital were required at the earliest stages of company creation. Innovation remained the order of the day, though pharma’s attempts to innovate looked strikingly similar to one another. We continued to see risk-sharing deal structures, emphasis on emerging markets, ongoing externalization and the biotech-ification of pharma, and stronger emphasis on “unmet medical need. Pharma also did more to work with VCs, payors, generics companies, and each other. The year saw a recovery in US drug approvals and launches, but the high prices associated with some of those new therapies and austerity in Europe also shed light on the health technology assessment-dominated future that likely faces most markets, including the US.

European Regulatory Round-Up: New Faces; Revised Guidances; More Cost Controls

A new chairman will take the helm of Germany's G-BA panel at a pivotal time for AMNOG implementation; the European Medicines Agency issues guidances in oncology drug development and genotoxicity; more regulatory updates.

Related Content

Topics

UsernamePublicRestriction

Register

PS053682

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel